WORLDglobal
Fresh hope for dementia patients as watchdog reviews decision not to offer blockbuster drugs on NHS
Single source
Updated 2 hours ago
First seen March 20, 2026 09:17:49Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are not currently available on NHS.